

Strategic Clinical Quality and Risk Management leader with 15+ years of progressive experience across biopharma R&D, spanning GxP Quality Assurance (GCP, GVP, GLP), Clinical Risk Management, Global Regulatory Inspection Readiness, Vendor Governance, and Biometrics Operations. Proven ability to build and operationalize Quality by Design frameworks, strengthen Quality Management Systems (QMS), and embed risk-based oversight models across global development programs. Deep expertise supporting FDA, EMA, and PMDA regulatory submissions and inspection readiness across hematology, immuno-oncology, and complex development portfolios. Experienced in leading cross-functional study teams, conducting internal and external audits evaluation guidance, driving CAPA effectiveness, developing Standard Operating Procedures and Work Instructions and performing quality due diligence for CROs and specialty vendors. Recognized for aligning quality strategy with enterprise R&D objectives, influencing senior leadership, and fostering a culture of Quality Excellence, accountability, and continuous improvement within fast-paced biotech and large pharmaceutical environments.